MCID: PLY105
MIFTS: 25

Polycystic Ovary Syndrome 1

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Polycystic Ovary Syndrome 1

MalaCards integrated aliases for Polycystic Ovary Syndrome 1:

Name: Polycystic Ovary Syndrome 1 54 13
Polycystic Ovary Syndrome 69

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant
probably heterogeneous


HPO:

32
polycystic ovary syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 184700

Summaries for Polycystic Ovary Syndrome 1

MalaCards based summary : Polycystic Ovary Syndrome 1, also known as polycystic ovary syndrome, is related to polycystic ovary syndrome, and has symptoms including hirsutism, amenorrhea and obesity. An important gene associated with Polycystic Ovary Syndrome 1 is PCOS1 (Polycystic Ovary Syndrome 1). The drugs Metformin and Cyproterone Acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and bone.

Description from OMIM: 184700

Related Diseases for Polycystic Ovary Syndrome 1

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 polycystic ovary syndrome 9.8

Symptoms & Phenotypes for Polycystic Ovary Syndrome 1

Symptoms via clinical synopsis from OMIM:

54

Hair:
hirsutism

Growth:
obesity

Misc:
response to bilateral wedge resection of the ovaries
increased frequency of early baldness or excessive hairiness in male first-degree relatives

GU:
amenorrhea
oligomenorrhea
enlarged polycystic ovaries

Endocrine:
no virilization

Lab:
normal 24-hr urinary ketosteroids
elevated dehydroepiandrosteronesulfate
increased 5-alpha-reductase activity in the liver and skin
elevated androstanedione and/or testosterone and luteinizing hormone
low estradiol and follicle-stimulating hormone levels
more

Clinical features from OMIM:

184700

Human phenotypes related to Polycystic Ovary Syndrome 1:

32 (show all 6)
id Description HPO Frequency HPO Source Accession
1 hirsutism 32 HP:0001007
2 amenorrhea 32 HP:0000141
3 obesity 32 HP:0001513
4 oligomenorrhea 32 HP:0000876
5 enlarged polycystic ovaries 32 HP:0008675
6 abnormality of metabolism/homeostasis 32 HP:0001939

UMLS symptoms related to Polycystic Ovary Syndrome 1:


pelvic pain

Drugs & Therapeutics for Polycystic Ovary Syndrome 1

Drugs for Polycystic Ovary Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
2
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757
4
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
5
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
6
Ganirelix Approved Phase 4,Early Phase 1 123246-29-7, 124904-93-4 25081094
7
Drospirenone Approved Phase 4,Phase 3,Phase 1 67392-87-4 68873
8
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 57-83-0 5994
9
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
10
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
11
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
12
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
13
Zinc Approved Phase 4,Early Phase 1 7440-66-6 32051 23994
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
15
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
16
Moxonidine Approved Phase 4 75438-57-2 4810
17
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3 616-91-1 12035
18
Liraglutide Approved Phase 4 204656-20-2 44147092
19
Leuprolide Approved, Investigational Phase 4,Phase 2 53714-56-0 3911 657181
20
Menotropins Approved Phase 4,Phase 1,Phase 2 61489-71-2, 9002-68-0 5360545
21
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
22
Citalopram Approved Phase 4 59729-33-8 2771
23
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
24 Racepinephrine Approved Phase 4
25
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
26
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
27
Alogliptin Approved Phase 4 850649-61-5 11450633
28
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
29
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
30
Tamoxifen Approved Phase 4 10540-29-1 2733526
31
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
32
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
33
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
36
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
37
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
39
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
40
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
41
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
42
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
43
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
44
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
45
Enclomiphene Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15690-57-0
46
Resveratrol Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0 445154
47
2,4-thiazolidinedione Investigational Phase 4,Early Phase 1 2295-31-0
48 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Androgen Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Androgens Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 536)

id Name Status NCT ID Phase Drugs
1 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
2 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
3 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
5 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
6 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
7 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
8 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
9 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
10 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
11 Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome Unknown status NCT01665547 Phase 4 l-carnitine
12 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
13 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
14 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
15 Metformin for the Treatment of Unexplained Oligozspermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
16 Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome Completed NCT00679679 Phase 4 Metformin;Placebo
17 Polycystic Ovary Syndrome - Improving Outcomes Completed NCT01504321 Phase 4 Moxonidine;Placebo
18 The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
19 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
20 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
21 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
22 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4 Liraglutide;placebo
23 Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4 Metformin;Placebo
24 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
25 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
26 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
27 The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4 clomiphene citrate with ethinyl esteradiol;clomiphene citrate with plasebo
28 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
29 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
30 Pioglitazone Treatment in Polycystic Ovary Syndrome Completed NCT00145340 Phase 4 pioglitazone
31 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4 Clomiphene citrate
32 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
33 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
34 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4 liraglutide;metformin
35 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
36 Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome Completed NCT00492882 Phase 4 usual administration of exogenous recombinant FSH
37 Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women Completed NCT01115140 Phase 4 metformin plus placebo;Metformin plus folic acid;placebo plus folic acid;placebo alone
38 Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS Completed NCT02352597 Phase 4 phytoestrogen;estradiol valerate;clomiphene citrate
39 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
40 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
41 The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS Completed NCT01961180 Phase 4 Cipralex;Placebo
42 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
43 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
44 Letrozole Versus Clomifene Citrate for Ovulation Induction Completed NCT00478504 Phase 4 Letrozole;Clomifene citrate
45 Metformin Suspension and Insulin Sensitivity Completed NCT00437333 Phase 4 Metformin cloridrate
46 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
47 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
48 Metformin and Oral Contraceptives in PCOS Completed NCT00451568 Phase 4 Metformin;Desorelle
49 Second-Line Treatments for Anovulatory Infertility in PCOS Patients Completed NCT00558077 Phase 4 Metformin plus clomiphene citrate
50 Epicardial Adipose Tissue Thickness in Polycystic Ovary Syndrome (PCOS) Completed NCT01258946 Phase 4

Search NIH Clinical Center for Polycystic Ovary Syndrome 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Polycystic Ovary Syndrome 1

Anatomical Context for Polycystic Ovary Syndrome 1

MalaCards organs/tissues related to Polycystic Ovary Syndrome 1:

39
Ovary, Liver, Bone, Brain, Heart, Pituitary, Endothelial

Publications for Polycystic Ovary Syndrome 1

Articles related to Polycystic Ovary Syndrome 1:

id Title Authors Year
1
The polycystic ovary syndrome. 1. Pathogenesis. ( 8012678 )
1994

Variations for Polycystic Ovary Syndrome 1

Expression for Polycystic Ovary Syndrome 1

Search GEO for disease gene expression data for Polycystic Ovary Syndrome 1.

Pathways for Polycystic Ovary Syndrome 1

GO Terms for Polycystic Ovary Syndrome 1

Sources for Polycystic Ovary Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....